Clinical Trial Search

Primary: Clearance Based on Photographic Scale — 2; 2; 4; 7 Participants

Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 Observations

Primary: Percentage of Participants With Change of Treated Lesions — 44; 44; 13 % of participants

Primary: Change From Baseline in a* and E at 8 Weeks — 1.27; 0.43; 4.08; 2.59 units on a scale

Primary: Change in Spots - Front of Face (Part 1) — 53.60; 58.47; 56.44 spots

Primary: MMSS for Scar Halves Treated — 8.4; 8.7 score on a scale

Primary: POSAS (The Patient and Observer Scar Assessment Scale) Measure — 2.5; 2.5; 2.5 Score

Primary: Change in Scar Pliability Between the Treated and Control Incision Sites as Measured by Skin Elasticity at 6 Months Compared to Baseline

Primary: Improvement in Surgical Scar of Treatment (532nm KTP Laser) and Active Control (595nm PDL) Treatment Arms. — 2.0; 1.5 score on a scale

Primary: Blanching of Port Wine Stain Birthmark — 16 participants

Primary: The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques. — 0 participants

Primary: Percent Clearance of All Lesions — 88; 96; 92.5; 0 percentage of lesion clearance

Primary: Photographic Evaluation of Scar Clearance — 1.82 score on a scale

Primary: The Change From Baseline to 30 Days After the Last Treatment in the Number of Senile Purpura Lesions — -3.55; -.35 number of purpuric lesions

Primary: Percent Change in Blanching of Port Wine Stain — 6; 5 percentage

Primary: Pigmented Lesion Improvement by Blinded Evaluation — 41 observations

Primary: Number Participants With Hypertropic Scarring, Keloid Formation, Hyper- or Hypopigmentation in Patients With Fitzpatrick Skin Types IV, V, and VI Receiving Nasolabial…

Primary: Change in Vectra Measured Length V1 (Month 0)-V2 (Month 3) for Original Group; Visit 3 (Month 6) to Visit 4 (Month 9) for Crossover Group — 0.10; 0.03 mm

Primary: Improvement of Surgical Scars at 12 Months Compared to Baseline (Pre-treatment) as Evaluated by 3 Independent Blinded Reviewers Using the General Aesthetic Improvement…

Primary: Change in Overall Improvement of Poikiloderma of Civatte (POC) From Baseline at 12 Weeks — 11.01; 6.03; 8.51; 5.89 percentage

Primary: Mean Change From Baseline in Erythema — -1.687; 5.730 units on a scale

Primary: Change in Dyspigmentation Spots — 48.3; 46; 42.2; 42.5 Dyspigmentation Spots

Primary: Improvement in Acne Scarring - From Baseline to Three Months After Last Treatment — 2; 2 score on a scale

Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05

Primary: Modified Patient and Observer Scar Assessment Scale Color Component Comparing Change From Baseline to Week 12. — -2.33 score on a scale

Primary: Severity Change in Acne Scarring — -2 score on a scale

Primary: Acne Scarring Improvement — 4; 4 score on a scale

Primary: Severity Assessment Score — -0.06; 0.2 score on a scale

Primary: Tumor Clearance — 2; 2; 5 Participants